Drug Trial Radar · NCT05315700
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
Mar 10, 2022
Primary completion
Jun 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- ORIC PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Apr 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.
Conditions
- Solid Tumors
Interventions
ORIC-114Drug
ORIC-114 oral daily
Chemotherapy drugDrug
21 days for up to 4 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase 2 Dose (RP2D)Time frame: 12 months
- Maximum plasma concentration (Cmax)Time frame: 28 Days
- Time of maximum observed concentration (Tmax)Time frame: 28 Days
- Area under the curve (AUC)Time frame: 28 Days
- Apparent plasma terminal elimination half-life (t1/2)Time frame: 28 Days
Locations
42 sites in 10 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
City of Hope
Huntington Beach, California · Recruiting
City of Hope
Irvine, California · Recruiting
City of Hope
Long Beach, California · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
Yale Cancer Center
New Haven, Connecticut · Recruiting
Georgetown University
Washington D.C., District of Columbia · Recruiting
Mayo Clinic
Jacksonville, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
NYU Langone Health Perlmutter Cancer Center
New York, New York · Recruiting
Duke Cancer Institute
Durham, North Carolina · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Spartanburg Regional Healthcare System
Spartanburg, South Carolina · Recruiting
Next Oncology
Fairfax, Virginia · Recruiting
Chris O'Brien Lifehouse
Camperdown, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Australia · Recruiting
One Clinical Research, Hollywood Medical Centre
Nedlands, Australia · Recruiting
Sydney Adventist Health
Sydney, Australia · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
The Chinese University of Hong Kong
Shatin, Hong Kong · Recruiting
Hospital Kuala Lumpur
Kuala Lumpur, Malaysia · Recruiting
University of Malaya Medical Center (UMMC)
Kuala Lumpur, Malaysia · Recruiting
Sultan Ahmad Shah Medical Centre at International Islamic University Malaysia (IIUM)
Kuantan, Pahang, Malaysia · Recruiting
Pulau Pinang Hospital
George Town, Pulau Pinang, Malaysia · Recruiting
Sarawak General Hospital (SGH)
Kuching, Sarawak, Malaysia · Recruiting
Medical University of Gdańsk
Gdansk, Poland · Recruiting
Chungbuk University Hospital
Cheongju-si, South Korea · Recruiting
National Cancer Center
Goyang-si, South Korea · Recruiting
Catholic University of Korea, St, Vincent Hospital
Gyeonggi-do, South Korea · Recruiting
Gachon University Hospital
Incheon, South Korea · Recruiting
Seoul National Bundang Hospital
Seongnam-si, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Severance Hospital, Yonsei University Health System
Seoul, South Korea · Recruiting
NEXT Oncology - Barcelona
Barcelona, Spain · Recruiting
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain · Recruiting
NEXT Oncology - Madrid
Madrid, Spain · Recruiting
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.